# GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

> **NCT06505486** · — · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 21 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine-Oxaliplatin Regimen

## Key facts

- **NCT ID:** NCT06505486
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-07-10
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06505486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06505486, "GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06505486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*